{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:35:08Z","timestamp":1761561308634},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2009,9]]},"DOI":"10.1007\/s00198-008-0826-5","type":"journal-article","created":{"date-parts":[[2009,1,20]],"date-time":"2009-01-20T10:26:13Z","timestamp":1232447173000},"page":"1499-1506","source":"Crossref","is-referenced-by-count":74,"title":["Antipsychotic use and the risk of hip\/femur fracture: a population-based case\u2013control study"],"prefix":"10.1007","volume":"20","author":[{"given":"S.","family":"Pouwels","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T. P.","family":"van Staa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. C. G.","family":"Egberts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. G. M.","family":"Leufkens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"de Vries","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,1,21]]},"reference":[{"key":"826_CR1","volume-title":"Pharmacology","author":"HP Rang","year":"1999","unstructured":"Rang HP et al (1999) Pharmacology, 4th edn. Churchill Livingstone, Edinburgh","edition":"4"},{"issue":"1","key":"826_CR2","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0022-3956(03)00094-3","volume":"38","author":"DV Jeste","year":"2004","unstructured":"Jeste DV, Dolder CR (2004) Treatment of non-schizophrenic disorders: focus on atypical antipsychotics. J Psychiatr Res 38(1):73\u2013103","journal-title":"J Psychiatr Res"},{"issue":"2","key":"826_CR3","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/pds.686","volume":"11","author":"CI Neutel","year":"2002","unstructured":"Neutel CI, Perry S, Maxwell C (2002) Medication use and risk of falls. Pharmacoepidemiol Drug Saf 11(2):97\u2013104","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"826_CR4","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/sj.mp.4001556","volume":"10","author":"S Miyamoto","year":"2005","unstructured":"Miyamoto S et al (2005) Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry 10(1):79\u2013104","journal-title":"Mol Psychiatry"},{"issue":"4","key":"826_CR5","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1046\/j.1365-2125.2001.01352.x","volume":"51","author":"KI Melkersson","year":"2001","unstructured":"Melkersson KI, Hulting AL, Rane AJ (2001) Dose requirement and prolactin elevation of antipsychotics in male and female patients with schizophrenia or related psychoses. Br J Clin Pharmacol 51(4):317\u2013324","journal-title":"Br J Clin Pharmacol"},{"issue":"20","key":"826_CR6","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.2165\/00003495-200464200-00003","volume":"64","author":"PM Haddad","year":"2004","unstructured":"Haddad PM, Wieck A (2004) Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 64(20):2291\u2013314","journal-title":"Drugs"},{"issue":"10","key":"826_CR7","doi-asserted-by":"crossref","first-page":"3572","DOI":"10.1523\/JNEUROSCI.21-10-03572.2001","volume":"21","author":"LD Kar Van de","year":"2001","unstructured":"Van de Kar LD et al (2001) 5-HT2A receptors stimulate ACTH, corticosterone, oxytocin, renin, and prolactin release and activate hypothalamic CRF and oxytocin-expressing cells. J Neurosci 21(10):3572\u20133579","journal-title":"J Neurosci"},{"issue":"12","key":"826_CR8","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.4088\/JCP.v65n1205","volume":"65","author":"M Misra","year":"2004","unstructured":"Misra M, Papakostas GI, Klibanski A (2004) Effects of psychiatric disorders and psychotropic medications on prolactin and bone metabolism. J Clin Psychiatry 65(12):1607\u20131618 quiz 1590, 1760\u20131761","journal-title":"J Clin Psychiatry"},{"key":"826_CR9","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1192\/bjp.184.6.503","volume":"184","author":"AM Meaney","year":"2004","unstructured":"Meaney AM et al (2004) Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia. Br J Psychiatry 184:503\u2013508","journal-title":"Br J Psychiatry"},{"issue":"1","key":"826_CR10","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/01.jcp.0000150223.31007.e0","volume":"25","author":"V O\u2019Keane","year":"2005","unstructured":"O\u2019Keane V, Meaney AM (2005) Antipsychotic drugs: a new risk factor for osteoporosis in young women with schizophrenia. J Clin Psychopharmacol 25(1):26\u201331","journal-title":"J Clin Psychopharmacol"},{"issue":"12","key":"826_CR11","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1001\/archinte.167.12.1240","volume":"167","author":"SJ Diem","year":"2007","unstructured":"Diem SJ et al (2007) Use of antidepressants and rates of hip bone loss in older women: the study of osteoporotic fractures. Arch Intern Med 167(12):1240\u20131245","journal-title":"Arch Intern Med"},{"issue":"2","key":"826_CR12","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1001\/archinte.167.2.188","volume":"167","author":"JB Richards","year":"2007","unstructured":"Richards JB et al (2007) Effect of selective serotonin reuptake inhibitors on the risk of fracture. Arch Intern Med 167(2):188\u2013194","journal-title":"Arch Intern Med"},{"key":"826_CR13","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1192\/bjp.bp.106.023671","volume":"190","author":"L Howard","year":"2007","unstructured":"Howard L, Kirkwood G, Leese M (2007) Risk of hip fracture in patients with a history of schizophrenia. Br J Psychiatry 190:129\u2013134","journal-title":"Br J Psychiatry"},{"issue":"6","key":"826_CR14","doi-asserted-by":"crossref","first-page":"414","DOI":"10.5694\/j.1326-5377.1993.tb121839.x","volume":"158","author":"RG Cumming","year":"1993","unstructured":"Cumming RG, Klineberg RJ (1993) Psychotropics, thiazide diuretics and hip fractures in the elderly. Med J Aust 158(6):414\u2013417","journal-title":"Med J Aust"},{"issue":"6","key":"826_CR15","doi-asserted-by":"crossref","first-page":"929","DOI":"10.4088\/JCP.v68n0616","volume":"68","author":"R Liperoti","year":"2007","unstructured":"Liperoti R et al (2007) Conventional or atypical antipsychotics and the risk of femur fracture among elderly patients: results of a case\u2013control study. J Clin Psychiatry 68(6):929\u2013934","journal-title":"J Clin Psychiatry"},{"issue":"7","key":"826_CR16","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1056\/NEJM198702123160702","volume":"316","author":"WA Ray","year":"1987","unstructured":"Ray WA et al (1987) Psychotropic drug use and the risk of hip fracture. N Engl J Med 316(7):363\u2013369","journal-title":"N Engl J Med"},{"issue":"6","key":"826_CR17","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s00198-005-0065-y","volume":"17","author":"P Vestergaard","year":"2006","unstructured":"Vestergaard P, Rejnmark L, Mosekilde L (2006) Anxiolytics, sedatives, antidepressants, neuroleptics and the risk of fracture. Osteoporos Int 17(6):807\u2013816","journal-title":"Osteoporos Int"},{"issue":"6","key":"826_CR18","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.bone.2005.07.005","volume":"37","author":"GW Hugenholtz","year":"2005","unstructured":"Hugenholtz GW et al (2005) Risk of hip\/femur fractures in patients using antipsychotics. Bone 37(6):864\u2013870","journal-title":"Bone"},{"issue":"3","key":"826_CR19","first-page":"93","volume":"1","author":"I Sernbo","year":"1987","unstructured":"Sernbo I, Hansson A, Johnell O (1987) Drug consumption in patients with hip fractures compared with controls. Compr Gerontol [A] 1(3):93\u201396","journal-title":"Compr Gerontol [A]"},{"issue":"1","key":"826_CR20","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1365-2710.2008.00878.x","volume":"33","author":"H Buurma","year":"2008","unstructured":"Buurma H et al (2008) Prevalence and determinants of pharmacy shopping behaviour. J Clin Pharm Ther 33(1):17\u201323","journal-title":"J Clin Pharm Ther"},{"issue":"1","key":"826_CR21","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/0895-4356(95)00552-8","volume":"49","author":"RM Herings","year":"1996","unstructured":"Herings RM et al (1996) Current use of thiazide diuretics and prevention of femur fractures. J Clin Epidemiol 49(1):115\u2013119","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"826_CR22","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1111\/j.1365-2796.2006.01754.x","volume":"261","author":"F Vries de","year":"2007","unstructured":"de Vries F et al (2007) Use of inhaled and oral glucocorticoids, severity of inflammatory disease and risk of hip\/femur fracture: a population-based case\u2013control study. J Intern Med 261(2):170\u2013177","journal-title":"J Intern Med"},{"issue":"6","key":"826_CR23","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/pds.1318","volume":"16","author":"F Vries de","year":"2007","unstructured":"de Vries F et al (2007) Use of beta-2 agonists and risk of hip\/femur fracture: a population-based case\u2013control study. Pharmacoepidemiol Drug Saf 16(6):612\u2013619","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"826_CR24","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s00223-006-0213-1","volume":"80","author":"F Vries de","year":"2007","unstructured":"de Vries F et al (2007) Use of beta-blockers and the risk of hip\/femur fracture in the United Kingdom and The Netherlands. Calcif Tissue Int 80(2):69\u201375","journal-title":"Calcif Tissue Int"},{"key":"826_CR25","unstructured":"WHO (2005) WHO Collaborating Centre for drug statistics methodology. The ATC\/DDD system. World Health Organisation"},{"issue":"7","key":"826_CR26","doi-asserted-by":"crossref","first-page":"761","DOI":"10.4088\/JCP.v64n0704","volume":"64","author":"D Becker","year":"2003","unstructured":"Becker D et al (2003) Risperidone, but not olanzapine, decreases bone mineral density in female premenopausal schizophrenia patients. J Clin Psychiatry 64(7):761\u2013766","journal-title":"J Clin Psychiatry"},{"key":"826_CR27","volume-title":"Applied therapeutics: the clinical use of drugs","author":"MA Koda-Kimble","year":"2003","unstructured":"Koda-Kimble MA, Young LY, Kradjan WA (2003) Applied therapeutics: the clinical use of drugs, 7th edn. . Lippincott, Williams & Wilkins, New York","edition":"7"},{"key":"826_CR28","volume-title":"Avery\u2019s drug treatment: A guide to the properties, choice, therapeutic use and economic value of drugs in disease management","author":"TM Speight","year":"1997","unstructured":"Speight TM, Holford NHG (1997) Avery\u2019s drug treatment: A guide to the properties, choice, therapeutic use and economic value of drugs in disease management, 4th edn. Adis Press, Auckland","edition":"4"},{"key":"826_CR29","unstructured":"AMAM (1996) American Medical Association. Division of Drugs and Toxicology. Drug Evaluations Annual, Chicago"},{"issue":"1","key":"826_CR30","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1176\/appi.ajp.162.1.162","volume":"162","author":"M Hummer","year":"2005","unstructured":"Hummer M et al (2005) Osteoporosis in patients with schizophrenia. Am J Psychiatry 162(1):162\u2013167","journal-title":"Am J Psychiatry"},{"issue":"Suppl","key":"826_CR31","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.1016\/S0920-9964(98)00158-3","volume":"35","author":"RG Petty","year":"1999","unstructured":"Petty RG (1999) Prolactin and antipsychotic medications: mechanism of action. Schizophr Res 35(Suppl):S67\u2013S73","journal-title":"Schizophr Res"},{"key":"826_CR32","volume-title":"Oxford textbook of medicine","author":"DA Warrel","year":"2005","unstructured":"Warrel DA, Cox TM, Firth JD (2005) Oxford textbook of medicine, vol. 3. 4th edn. Oxford University Press, Oxford","edition":"4"},{"key":"826_CR33","first-page":"599","volume-title":"Osteoporosis","author":"JA Grisso","year":"1996","unstructured":"Grisso JA, Capezuti E, Schwartz A (1996) Falls as risk factors for fractures. In: Marcus D, Kelsey J, Feldman D (eds) Osteoporosis. Academic, San Diego, pp 599\u2013611"},{"issue":"12","key":"826_CR34","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1056\/NEJM199503233321202","volume":"332","author":"SR Cummings","year":"1995","unstructured":"Cummings SR et al (1995) Risk factors for hip fracture in white women. Study of osteoporotic fractures research group. N Engl J Med 332(12):767\u2013773","journal-title":"N Engl J Med"},{"key":"826_CR35","doi-asserted-by":"crossref","DOI":"10.1017\/CBO9780511544163","volume-title":"A guide to the extrapyramidal side-effects of antipsychotic drugs","author":"DC Owens","year":"1999","unstructured":"Owens DC (1999) A guide to the extrapyramidal side-effects of antipsychotic drugs. Cambridge University Press, Cambridge"},{"issue":"2","key":"826_CR36","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00198-004-1640-3","volume":"16","author":"JA Kanis","year":"2005","unstructured":"Kanis JA et al (2005) Smoking and fracture risk: a meta-analysis. Osteoporos Int 16(2):155\u2013162","journal-title":"Osteoporos Int"},{"issue":"12","key":"826_CR37","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1007\/s00198-005-1866-8","volume":"16","author":"JA Cauley","year":"2005","unstructured":"Cauley JA et al (2005) Factors associated with the lumbar spine and proximal femur bone mineral density in older men. Osteoporos Int 16(12):1525\u20131537","journal-title":"Osteoporos Int"},{"issue":"3","key":"826_CR38","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/gps.1462","volume":"21","author":"HM Alanen","year":"2006","unstructured":"Alanen HM et al (2006) Use of antipsychotic medications among elderly residents in long-term institutional care: a three-year follow-up. Int J Geriatr Psychiatry 21(3):288\u2013295","journal-title":"Int J Geriatr Psychiatry"},{"issue":"5","key":"826_CR39","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1038\/sj.npp.1301492","volume":"33","author":"DV Jeste","year":"2008","unstructured":"Jeste DV et al (2008) ACNP white paper: update on use of antipsychotic drugs in elderly persons with dementia. Neuropsychopharmacology 33(5):957\u2013970","journal-title":"Neuropsychopharmacology"},{"key":"826_CR40","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/j.1532-5415.1994.tb06859.x","volume":"42","author":"LJ Melton III","year":"1994","unstructured":"Melton LJ III et al (1994) Fracture risk in patients with Alzheimer\u2019s disease. J Am Geriatr Soc 42:614\u2013619","journal-title":"J Am Geriatr Soc"},{"key":"826_CR41","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/S8756-3282(02)00848-7","volume":"31","author":"TP Staa van","year":"2002","unstructured":"van Staa TP et al (2002) Utility of medical and drug history in fracture risk prediction among men and women. Bone 31:508\u2013514","journal-title":"Bone"},{"issue":"5","key":"826_CR42","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1001\/archinte.159.5.484","volume":"159","author":"MA Whooley","year":"1999","unstructured":"Whooley MA et al (1999) Depression, falls, and risk of fracture in older women. Arch Intern Med 159(5):484\u2013490","journal-title":"Arch Intern Med"},{"issue":"4","key":"826_CR43","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1097\/JCP.0b013e31817d5943","volume":"28","author":"JM Bolton","year":"2008","unstructured":"Bolton JM et al (2008) Fracture risk from psychotropic medications: a population-based analysis. J Clin Psychopharmacol 28(4):384\u2013391","journal-title":"J Clin Psychopharmacol"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-008-0826-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,14]],"date-time":"2020-05-14T21:01:00Z","timestamp":1589490060000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-008-0826-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1,21]]},"references-count":43,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2009,9]]}},"alternative-id":["826"],"URL":"https:\/\/doi.org\/10.1007\/s00198-008-0826-5","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,1,21]]}}}